Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about Gardasil's expected revenue, which has led to significant stock price declines [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, driven by consumer activation and education efforts [1]. - On February 4, 2025, Merck announced it would not achieve the projected$11 billion in sales, ceasing shipments to China to reduce inventory due to lower-than-expected demand, resulting in a stock price drop from $99.79 to$90.74, a decline of over 9% in one day [1]. Group 2: Class Action Details - Shareholders who purchased MRK shares during the class period from February 3, 2022, to February 3, 2025, are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].